Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer’s Disease

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med 2011, 3: 77sr71.

    Google Scholar 

  2. 2.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132: 2131–2157.

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001, 142: 521–527.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Andersen A, Lund A, Knop FK, Vilsboll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018, 14: 390–403.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang H-Y, Ahima RS, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 2018, 14: 168–181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Najem D, Bamji-Mirza M, Yang Z, Zhang W. Aβ-induced insulin resistance and the effects of insulin on the cholesterol synthesis pathway and Aβ secretion in neural cells. Neurosci Bull 2016, 32: 227–238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Holscher C. Drugs developed for treatment of diabetes show protective effects in Alzheimer’s and Parkinson’s diseases. Acta Physiol Sin 2014, 66: 497–510.

    Google Scholar 

  8. 8.

    During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9: 1173–1179.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer’s disease. Behav Brain Res 2009, 205: 265–271.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Li T, Jiao JJ, Holscher C, Wu MN, Zhang J, Tong JQ, et al. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3×Tg mouse model of Alzheimer’s disease. Hippocampus 2018, 28: 358–372.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Perry TL, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003, 72: 603–612.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Gault VA, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008, 587: 112–117.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    McClean PL, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci 2011, 31: 6587–6594.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Ma T, Klann E. Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer’s disease. J Neurochem 2012, 120 Suppl 1: 140–148.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Giacco F, Du X, Carratú A, Gerfen GJ, D’Apolito M, Giardino I, et al. GLP-1 Cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop. Diabetes 2015, 64: 3273–3284.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E. Glucagon-like peptide-1 cleavage product GLP-1 (9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer’s Disease Model Mice. J Neurosci 2012, 32: 13701–13708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007, 53: 703–717.

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Ma T, Tzavaras N, Tsokas P, Landau EM, Blitzer RD. Synaptic stimulation of mTOR is mediated by Wnt signaling and regulation of glycogen synthetase kinase-3. J Neurosci 2011, 31: 17537–17546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J Neurochem 2008, 104: 1433–1439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Ma T. GSK3 in Alzheimer’s disease: mind the isoforms. J Alzheimers Dis 2014, 39: 707–710.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This insight was supported by the National Institutes of Health, USA (K99/R00 AG044469, R01 AG055581, and R01 AG056622), and the BrightFocus Foundation (A2017457S).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tao Ma.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Day, S.M., Ma, T. Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer’s Disease. Neurosci. Bull. 35, 934–936 (2019). https://doi.org/10.1007/s12264-019-00355-y

Download citation